Source: Kapitales Research Highlights

• ResMed Inc. agrees to sell MatrixCare business in a US$490 million all-cash deal.
• Transaction proceeds will support shareholder returns and future growth initiatives.
• Company sharpens its focus on sleep health and connected homecare technologies.

ResMed Inc. (ASX: RMD) traded at AU$31.60, up 0.51%, after announcing a significant portfolio optimisation move. The company announced plans to sell its MatrixCare business to Frazier Healthcare Partners through an all-cash transaction valued at US$490 million, pending regulatory approvals and the fulfilment of customary closing conditions.

Business Divestment Sharpens Strategic Focus

The deal is anticipated to be finalised in the first quarter of ResMed's fiscal 2027, pending the completion of customary regulatory requirements. Following completion, ResMed Inc. intends to use the net proceeds to return capital to shareholders through an accelerated share repurchase program while also supporting general corporate purposes. The divestment aligns with the company's long-term strategy of concentrating investments in high-growth areas such as sleep health, breathing care and connected home-based healthcare solutions.

Financial Impact and Growth Outlook

According to preliminary fiscal 2026 results, the MatrixCare business generated approximately US$220 million in revenue and around US$55 million in non-GAAP operating profit. Meanwhile, ResMed's recently completed acquisition of Noctrix is expected to contribute roughly US$30 million in revenue during fiscal 2027, although it is projected to reduce non-GAAP diluted EPS by approximately US$0.20. The company also reaffirmed its previously issued fiscal 2026 guidance and expects its Residential Care Software segment to deliver high single-digit year-over-year revenue growth in fiscal 2027.

Outlook

The divestment highlights ResMed Inc.'s disciplined capital allocation strategy and its commitment to expanding leadership in higher-growth healthcare technology markets. Investors are expected to monitor upcoming earnings for additional insights into fiscal 2027 performance and the execution of the planned capital return initiatives.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au